NeuroFate: endpoint-locked transcriptomic axis scoring for neurodegeneration risk research
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Motivation
AD and PD transcriptomic cohorts can reveal disease-associated neuronal, glial, mitochondrial, myelin, proteostasis, vascular, and immune programs, but these signals are difficult to compare reproducibly across studies without endpoint-locked, sample-level biological summaries.
Results
We present NeuroFate, a command-line research package that converts compact transcriptomic cohorts into curated neurodegeneration-axis scores, exploratory research-use risk scores, and conservative evidence reports. The software locks disease-state endpoints before scoring, maps genes or probes onto a 10-axis NeuroFate panel, records axis-gene coverage, and grades external cohort evidence by direction, effect size, nominal/FDR support, and claim-safety rules. Demonstrations across AD and PD resources show nominal independent AD support for a neuronal vulnerability axis, mixed PD convergence, and a PD-divergent synuclein–mitochondrial example while avoiding clinical or mechanism-overstating claims.
Availability and implementation
NeuroFate is implemented in Python and available at https://github.com/sinhakrishnendu/NeuroFate.git .
Contact
nabanitaghosh89@gmail.com ; dr.krishnendusinha@gmail.com .
Supplementary information
Documentation, examples, tests, and reproducibility notes are included in the repository.
